<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26925113</article-id><article-id pub-id-type="pmc">4754364</article-id><article-id pub-id-type="publisher-id">26836</article-id><article-id pub-id-type="doi">10.5114/aoms.2016.57577</article-id><article-categories><subj-group subj-group-type="heading"><subject>State of the Art Paper</subject></subj-group></article-categories><title-group><article-title>Chromogranin A &#x02013; unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gut</surname><given-names>Pawe&#x00142;</given-names></name></contrib><contrib contrib-type="author"><name><surname>Czarnywojtek</surname><given-names>Agata</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fischbach</surname><given-names>Jakub</given-names></name></contrib><contrib contrib-type="author"><name><surname>B&#x00105;czyk</surname><given-names>Maciej</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ziemnicka</surname><given-names>Katarzyna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wrotkowska</surname><given-names>El&#x0017c;bieta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gryczy&#x00144;ska</surname><given-names>Maria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rucha&#x00142;a</surname><given-names>Marek</given-names></name></contrib></contrib-group><aff>Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Pawe&#x00142; Gut PhD, Department of Endocrinology, Metabolism and Internal Diseases, University of Medical Sciences, 49 Przybyszewskiego St, 60-355 Poznan, Poland. Phone: +48 61 869 13 30, +48 607 39 29 22, Fax: +48 61 869 16 82. E-mail: <email xlink:href="gutpj@poczta.onet.pl">gutpj@poczta.onet.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>2</month><year>2016</year></pub-date><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><history><date date-type="received"><day>10</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Termedia &#x00026; Banach</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><p>Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration.</p></abstract><kwd-group><kwd>chromogranin A</kwd><kwd>neuroendocrine tumors</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>The growing interest in neuroendocrine tumors, which are interdisciplinary diseases, is associated with an increase in their detection in recent years. Due to their usually indolent character we are dealing with a metastatic proliferative process at the time of diagnosis. Therefore, as in other neoplasms, attempts are made to use biochemical markers that could serve as a valuable diagnostic tool and indicator of response to treatment or recurrence of the disease. The marker for neuroendocrine tumors is chromogranin A, which often in the absence of other biochemical markers of the disease is a useful factor in both the diagnosis and monitoring of disease. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. In this review, we would like to present the current state of knowledge about the usefulness of this marker in neuroendocrine tumors and provide a number of conditions that can give false positive results.</p></sec><sec id="S0002"><title>General characteristics</title><p>Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The family consists of 8 granin proteins: chromogranin A, B, C (secretogranin II), secretogranin III, IV, V, VI, and VEGF. Granins potentially play an essential role in the creation, maturation and exocytosis of secretory vesicles containing biologically active neuropeptides, neurotransmitters and hormones. Their molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins.</p><p>Chromogranin A (CgA) was the first identified representative of granins, and derives its name from the spot of primary detection (adrenal medulla chromaffin vesicles containing catecholamines) [<xref rid="CIT0001" ref-type="bibr">1</xref>, <xref rid="CIT0002" ref-type="bibr">2</xref>]. It is encoded by the gene CHGA/CgA located on chromosome 14. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. From the 439-amino acid chain of chromogranin A there arise a number of peptides:<list list-type="bullet"><list-item><p>vasostatin I &#x02013; exhibiting antiadrenergic activity [<xref rid="CIT0003" ref-type="bibr">3</xref>],</p></list-item><list-item><p>parastatin &#x02013; inhibiting secretion of parathyroid hormone in response to low levels of calcium [<xref rid="CIT0004" ref-type="bibr">4</xref>],</p></list-item><list-item><p>pancreastatin &#x02013; showing a strong inhibitory effect on insulin secretion induced by increasing concentration of glucose in the blood [<xref rid="CIT0005" ref-type="bibr">5</xref>],</p></list-item><list-item><p>catestatin &#x02013; inhibiting secretion of catecholamines from the chromaffin cells [<xref rid="CIT0006" ref-type="bibr">6</xref>].</p></list-item></list>
</p><p>To date, knowledge about the other products of chromogranin A proteolysis (vasostatin II, chromostatin, GE-25, EC-14) is scant and their biological effect is not certain [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Interestingly, proteolysis of chromogranin appears to be organ specific. For example, pancreastatin found in the &#x003b1; cells of the pancreas is absent in adrenal medulla chromaffin cells [<xref rid="CIT0008" ref-type="bibr">8</xref>].</p></sec><sec id="S0003"><title>Methods for determination of chromogranin</title><p>There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. Three diagnostic techniques are available: enzyme-linked immunosorbent assay (ELISA), immunoradiometric assay (IRMA) and radioimmunoassay (RIA). There is no standardization for any of the techniques: different studies use different antibodies, which in turn react with different antigenic epitopes on the surface of the protein chain. Determination of CgA by different techniques leads to significant differences in results, with varying effects on sensitivity and specificity. Currently there is no universal, worldwide accepted diagnostic technique; thus caution is recommended when trying to compare the results from different research centers. Chromogranin can be measured from plasma or serum. It has been reported that plasma chromogranin tends to be markedly higher than that determined in the serum [<xref rid="CIT0009" ref-type="bibr">9</xref>]. There are many studies comparing the sensitivity and specificity of available diagnostic methods. Stridsberg <italic>et al</italic>. compared all 3 methods. For IRMA sensitivity was 67% and specificity 96%, for ELISA sensitivity was 85% and specificity 85%, and for RIA sensitivity was 93% and specificity 85%, suggesting that the best compromise between sensitivity and specificity is the use of RIA [<xref rid="CIT0010" ref-type="bibr">10</xref>].</p></sec><sec id="S0004"><title>Chromogranin A &#x02013; potentially false positive results</title><p>Because of wide spectrum chromogranin A secretion, together with other regulatory proteins, there are several causes of elevated chromogranin unrelated to neuroendocrine tumor. In clinical practice, the most common causes of false (non-NET) CgA results is the use of proton pump inhibitors, cases of atrophic gastritis and impaired kidney function. The majority of false positive results are about 2&#x02013;4 times higher than the upper reference range, but a significant number of these results may reach up to 5&#x02013;20 times higher than the upper reference range [<xref rid="CIT0011" ref-type="bibr">11</xref>].</p><sec id="S20005"><title>Gastric disorders</title><p>Elevated CgA levels are observed in cases of atrophic gastritis or during treatment with proton pump inhibitors (PPIs) and other acid suppressive medications. Lack of gastric acids engenders hypergastrinemia due to no negative feedback for gastrin, which in turn stimulates the growth of enterochromaffin cells to secrete CgA. Therefore, we obtain elevated circulating CgA. The PPI therapy may increase CgA concentration just 5 days after the first intake and leads to CgA 5&#x02013;10 times higher than the upper reference range, results often seen in patients with early stage NET [<xref rid="CIT0012" ref-type="bibr">12</xref>]. To prevent any impact on the value of CgA by PPIs, a drug should be discontinued at least 7 days before the test. It should also be remembered that the longer PPI therapy lasts, the longer is the time needed for the normalization of CgA concentration. Histamine type-2 receptor antagonists (H2RA) may also have an effect on the increase of the marker. It is suggested to discontinue these medications for at least 24 h before the scheduled CgA examination.</p></sec><sec id="S20006"><title>Impaired kidney function</title><p>Elevated CgA also occurs in the case of impaired kidney function due to reduced renal clearance. The higher the degree of renal failure, the higher the CgA concentration, and the result may reach the level found in neuroendocrine tumors [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Before interpreting the result of CgA as a marker of NET, renal function should be evaluated carefully to rule out the potential impact on the concentration of CgA. Evaluation of CgA as a marker of NET in the case of end stage renal disease is impossible.</p></sec><sec id="S20007"><title>Heart diseases</title><p>In a study of 160 patients with chronic heart failure, CgA concentration was significantly higher than in healthy volunteers. CgA levels correlated with the intensity of heart failure defined on the basis of the NYHA scale. Patients in the fourth grade showed the highest concentration of circulating CgA. It was further found that the concentration of chromogranin A is an independent marker of mortality [<xref rid="CIT0014" ref-type="bibr">14</xref>]. Interestingly, in patients with chronic heart failure, CgA levels did not correlate with the concentration of the hormones that are involved in the pathophysiological basis of the disease, including catecholamines and components of the renin-angiotensin-aldosterone system [<xref rid="CIT0015" ref-type="bibr">15</xref>]. CgA concentration in this case correlated with the concentration of brain natriuretic peptide (BNP) [<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0017" ref-type="bibr">17</xref>]. Elevated chromogranin A is also observed in cases of acute coronary syndromes, where a high concentration of the peptide significantly worsens the prognosis [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Circulating CgA seems to reflect inflammation and cardiac overload rather than activation of the autonomous nervous system. In this case, CgA showing a negative inotropic and lusitropic effect plays a protective role in preventing excessive activation of the heart muscle in response to stress factors [<xref rid="CIT0016" ref-type="bibr">16</xref>].</p></sec><sec id="S20008"><title>Hypertension</title><p>There is a high concentration of CgA in the case of untreated hypertension, and CgA levels may correlate with the severity of hypertension in conjunction with increased adrenergic activity.</p></sec><sec id="S20009"><title>Rheumatoid diseases</title><p>In rheumatoid arthritis, the concentration of CgA correlates with the concentration of the receptors for tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and treatment with anti-TNF-&#x003b1; impairs this correlation, suggesting a connection between these two molecules. Interestingly, patients with generalized disease manifestations showed unusually high concentrations of CgA, which were sometimes even higher than those observed in patients with neuroendocrine tumors, compared with patients with disease limited only to joints. The CgA concentration seems to reflect generalized inflammation and, by its derivative vasostatin 1, exhibits a protective effect on the endothelium by inhibiting inflammation mediated by TNF-&#x003b1; [<xref rid="CIT0019" ref-type="bibr">19</xref>]. Elevated CgA is also observed in other rheumatoid diseases such as systemic lupus erythematosus.</p></sec><sec id="S20010"><title>Inflammatory bowel disease</title><p>Many patients with neuroendocrine tumors derived from the midgut are initially erroneously diagnosed with irritable bowel syndrome, sometimes even a few years before the correct diagnosis. There are reports of an increased concentration of CgA in irritable bowel syndrome and inflammatory bowel disease. Therefore evaluation of CgA is not valuable as a screening test in the evaluation of uncertain cause diarrhea [<xref rid="CIT0020" ref-type="bibr">20</xref>]. Approximately 50% of patients with inflammatory bowel diseases tend to have elevated CgA, especially in the case of the active phase of the disease [<xref rid="CIT0021" ref-type="bibr">21</xref>].</p></sec><sec id="S20011"><title>Other causes</title><p>Worthy of note is the fact that in both healthy individuals and patients with neuroendocrine tumors CgA increases under the influence of food intake and exercise. Maximum CgA concentrations are observed 30&#x02013;90 min after a meal and reach 2&#x02013;3 times the upper reference range [<xref rid="CIT0022" ref-type="bibr">22</xref>]. Therefore it is recommended to measure CgA after rest and fasting. Differences in concentration of CgA measured day by day can be up to 20%, and this phenomenon is observed in both healthy volunteers and patients with NET [<xref rid="CIT0023" ref-type="bibr">23</xref>]. For other potential causes of false-positive results of chromogranin A see <xref ref-type="table" rid="T0001">Tables I</xref> and <xref ref-type="table" rid="T0002">II</xref>.</p><table-wrap id="T0001" position="float"><label>Table I</label><caption><p>Factors affecting the concentration of chromogranin A</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Factor</th><th align="center" rowspan="1" colspan="1">False positive results</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Diseases of the cardiovascular system</td><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, heart failure, acute coronary syndrome</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Renal diseases</td><td valign="top" align="left" rowspan="1" colspan="1">Impaired kidney function/renal insufficiency</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diseases of the alimentary tract</td><td valign="top" align="left" rowspan="1" colspan="1">Chronic atrophic gastritis, inflammatory bowel diseases, irritable bowel syndrome, pancreatitis, chronic hepatitis, liver cirrhosis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-neuroendocrine neoplasms</td><td valign="top" align="left" rowspan="1" colspan="1">Prostate cancer, ovarian cancer, breast cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, hematological malignancies</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inflammatory diseases</td><td valign="top" align="left" rowspan="1" colspan="1">Systemic rheumatoid arthritis, systemic lupus erythematosus, COPD</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Endocrine disorders</td><td valign="top" align="left" rowspan="1" colspan="1">Pheochromocytoma, hyperparathyroidism, hyperthyroidism, medullary thyroid cancer, pituitary tumors (except prolactinomas), hypercortisolemia</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medications</td><td valign="top" align="left" rowspan="1" colspan="1">Proton pump inhibitors, histamine type-2 receptor antagonists</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="left" rowspan="1" colspan="1">Food intake or strenuous exercise before the test</td></tr></tbody></table></table-wrap><table-wrap id="T0002" position="float"><label>Table II</label><caption><p>Metabolism of chromogranin A. Neuroendocrine and non-neuroendocrine diseases with elevated chromogranin A concentration in serum</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1">Neuroendocrine diseases</th><th align="center" rowspan="1" colspan="1">Non-neuroendocrine diseases</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Pheochromocytoma</p></list-item><list-item><p>Neuroblastoma</p></list-item><list-item><p>Medullary thyroid carcinoma</p></list-item><list-item><p>Pituitary adenomas (acromegaly)</p></list-item><list-item><p>Primary hyperparathyroidism</p></list-item><list-item><p>Hormonal activity of fetal placenta</p></list-item><list-item><p>Hypercortisolism</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Renal failure</p></list-item><list-item><p>Chronic atrophic gastritis type A</p></list-item><list-item><p>Crohn's disease, ulcerative colitis</p></list-item><list-item><p>Rheumatoid arthritis</p></list-item><list-item><p>Parkinson's disease</p></list-item><list-item><p>Steroid treatment</p></list-item></list>
</td></tr></tbody></table></table-wrap></sec></sec><sec id="S0012"><title>Chromogranin A and neuroendocrine tumors</title><p>The CgA is secreted by a number of neuroendocrine tumors, which broadly include: pheochromocytoma, medullary thyroid carcinoma, parathyroid adenomas, pulmonary neuroendocrine tumors including small cell lung cancer, and finally gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Nobels <italic>et al</italic>. evaluated the usefulness of determining the concentration of chromogranin A as a marker of tumors in different disease entities [<xref rid="CIT0024" ref-type="bibr">24</xref>].</p><p>The concentration of chromogranin A was elevated in 100% of cases of gastrinomas, in 89% of pheochromocytomas, 80% of neuroendocrine tumors of the small intestine, 69% of non-functioning pancreatic neuroendocrine tumors and in the case of medullary thyroid cancer concentrations above the reference range were recorded in 50% of cases. What is important, in 7% of cases in the control group elevated CgA was also observed.</p></sec><sec id="S0013"><title>Chromogranin A and non-neuroendocrine neoplasms</title><p>Elevated chromogranin in cases of prostate cancer shows neuroendocrine differentiation of tumor tissue, which is associated with progression, poor prognosis and resistance to hormonal therapy [<xref rid="CIT0025" ref-type="bibr">25</xref>]. Elevated concentrations were also observed in the case of other types of cancer: breast cancer, cancer of the digestive gland, cancer of the female genital tract, hematological malignancies and cancers of the head and neck [<xref rid="CIT0026" ref-type="bibr">26</xref>]. In studies assessing CgA levels in neoplasms other than neuroendocrine tumors and small cell lung cancer there was no difference between serum CgA and tumor size [<xref rid="CIT0027" ref-type="bibr">27</xref>, <xref rid="CIT0028" ref-type="bibr">28</xref>]. These data are surprising because most tumor markers correlate with tumor size or progression of the disease. Markers are significantly higher in the case of disseminated neoplastic processes. This situation indicates that elevated CgA cannot be used to assess the severity or progression of the disease in tumors other than those of neuroendocrine origin.</p></sec><sec id="S0014"><title>Chromogranin A and gastroenteropancreatic neuroendocrine tumors</title><sec id="S20015"><title>Chromogranin A concentration and staging</title><p>In general, the highest values of CgA and accuracy in the determination of CgA are observed the most frequently in tumors showing intense secretory activity, mainly neuroendocrine tumors of the small intestine, particularly causing carcinoid syndrome (midgut neuroendocrine tumors) [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Chromogranin A is significantly higher in the case of disseminated rather than limited neoplastic disease. An exception may be a gastrinoma, as here CgA is high even in the absence of metastases in the liver [<xref rid="CIT0030" ref-type="bibr">30</xref>]. In the case of midgut tumors the comparison of CgA concentration and severity of disease was performed. Patients with multiple liver metastatic disease demonstrated a significantly higher concentration of CgA than patients with only a few lesions in the liver or lymph node metastases [<xref rid="CIT0031" ref-type="bibr">31</xref>]. Satisfactory accuracy of CgA is also observed in hormonally inactive cases of neuroendocrine tumors [<xref rid="CIT0032" ref-type="bibr">32</xref>]. The CgA is described as a prognostic marker for GEP-NET: high levels correlate with shorter survival and liver cancer burden. Chromogranin A concentrations and sensitivity depend mainly on the spread of cancer. Arnold <italic>et al</italic>. reported that the accumulation of metastatic changes in the liver significantly increases the concentration of CgA. In addition, the appearance of metastases to lymph nodes in previously proven metastases in the liver did not cause a further increase in the value of CgA [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Moreover, Janson <italic>et al</italic>. observed a significantly higher CgA concentration in the case of multiple metastatic lesions in the liver (&#x0003e; 5) in comparison to the case of only a few metastases (&#x0003c; 5) or only lymph metastases [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Walter <italic>et al</italic>. reported that CgA levels are significantly elevated more frequently in the case of NET metastases compared to reduced cancer (74% vs. 51%) [<xref rid="CIT0034" ref-type="bibr">34</xref>].</p></sec><sec id="S20016"><title>Chromogranin A and tumor primary location and grading</title><p>Taking into account the relationship between the tumor primary location and sensitivity of CgA, most data show higher sensitivity in the case of midgut neuroendocrine tumors compared with pancreatic neuroendocrine tumors [<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0030" ref-type="bibr">30</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>]. The highest values of CgA are observed in small intestine neuroendocrine tumors (up to 200 times above normal) and GEP-NETs occurring in MEN-1 syndrome (up to 150 times above normal). As regards the pancreatic neuroendocrine tumors, both functioning and non-functioning tumors reveal intermediate levels of CgA (up to 60&#x02013;80 times the upper reference). In the case of Zollinger-Ellison syndrome connected with MEN1 syndrome, and in the case of type II and III gastric neuroendocrine tumors, values are up to 80&#x02013;100 times higher than the upper reference range [<xref rid="CIT0037" ref-type="bibr">37</xref>]. The sensitivity and specificity of CgA for different types of neuroendocrine tumors are in the range 60&#x02013;100% and 70&#x02013;100%, respectively, with the highest values observed in the case of serotonin-secreting neuroendocrine tumors (carcinoid tumors) [<xref rid="CIT0038" ref-type="bibr">38</xref>, <xref rid="CIT0039" ref-type="bibr">39</xref>]. In the case of serotonin-secreting neuroendocrine tumors originating from the midgut, CgA concentration is an independent prognostic factor, because its concentration is correlated not only with the size of the tumor but also with the intensity of biological activity [<xref rid="CIT0040" ref-type="bibr">40</xref>].</p></sec><sec id="S20017"><title>Chromogranin A as a prognostic factor</title><p>Chromogranin A concentration can be used as an indirect predictor of cancer. There is a correlation between the staging of the disease and concentration of CgA. As mentioned above, higher CgA is observed for metastatic disease compared to localized disease [<xref rid="CIT0041" ref-type="bibr">41</xref>]. There are reports of a correlation between CgA and survival in neuroendocrine tumors. A concentration 3 times above the upper reference range at the time of diagnosis is a significant predictor of shorter survival (hazard ratio 2.6) in patients with pancreatic neuroendocrine tumors [<xref rid="CIT0042" ref-type="bibr">42</xref>]. In the case of neuroendocrine tumors of the midgut, CgA level &#x0003e; 5000 &#x000b5;g/l was an independent predictor of shorter survival of patients, and comparing the results of &#x0003e; 5000 &#x000b5;g/l and &#x0003c; 5000 &#x000b5;g/l, the median survival was 33 months and 57 months, respectively [<xref rid="CIT0031" ref-type="bibr">31</xref>]. Elevated CgA was associated with significantly shorter survival in the study of midgut tumors with liver metastases treated with a long-acting somatostatin analog, while no relationship between survival and concentrations of urinal 5-hydroxyindoleacetic acid (5-HIAA), the breakdown product of serotonin, was observed [<xref rid="CIT0043" ref-type="bibr">43</xref>]. Worthy of note is the fact that the correlation between serum CgA and survival cannot be used generally in relation to GEP-NETs. Gastrinoma are associated with high levels of chromogranin A in serum, even in the absence of metastases in the liver, which is associated with the above-mentioned enterochromaffin cell stimulation by gastrin, in this case with non-negative feedback.</p></sec><sec id="S20018"><title>Chromogranin A and relapse of the disease</title><p>In a retrospective study of 56 patients with NET, the concentration of CgA was the first indication of the recurrence of the proliferative process after radically carried out surgery. It suggests that the periodic evaluation of CgA may be a more preferred method than repeated radiological procedures in a situation where we have delayed with complete tumor resection previously [<xref rid="CIT0044" ref-type="bibr">44</xref>]. The concentration of chromogranin A correlates with the size and extent of cancer; thus its periodic measurement may be helpful in detecting potential recurrence of the disease. A study evaluating the usefulness of CgA in monitoring of radically treated neuroendocrine tumors showed that the increase in CgA is the first marker of recurrence of the disease, which occurs before changes in the concentration of urinal 5-hydroxyindoleacetic acid or radiologic recurrence [<xref rid="CIT0044" ref-type="bibr">44</xref>].</p><p>The same study showed that in 86% of patients with elevated chromogranin A the recurrence of the disease was present subsequently (33 of 56 patients, at a median of 32 months). Another study showed that among patients with GEP-NETs of different locations, who experienced progression of the disease, elevated CgA concentrations were observed in 83% of cases, while in patients with liver metastasis progression this result was observed in 100% of cases [<xref rid="CIT0045" ref-type="bibr">45</xref>].</p></sec><sec id="S20019"><title>Chromogranin A and response to treatment</title><p>In cases of radically operated neuroendocrine tumors originating from the midgut, CgA levels were recorded as both a diagnostic and early relapse marker. Reduction of CgA concentration is used frequently as an indicator of response to treatment in clinical trials, in which the biochemical response is usually defined as a &#x02265; 50% reduction in the concentration of CgA [<xref rid="CIT0033" ref-type="bibr">33</xref>, <xref rid="CIT0044" ref-type="bibr">44</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>]. It is assumed that the reduction of CgA by more than 50% may be a proof of the correct choice of treatment. Assuming that the concentration of CgA correlates with the size and number of malignancies, the concentration of CgA is theoretically expected to decrease if treatment is effective. The study by Nehara <italic>et al</italic>. provided data indicating the reduction of circulating CgA concentration after resection or cytoreduction of the neuroendocrine tumor [<xref rid="CIT0041" ref-type="bibr">41</xref>]. In the case of the use of different non-invasive methods also a correlation between the response to treatment of GEP-NET and the concentration of CgA was noted. It occurred as a reduction or stabilization of its concentration [<xref rid="CIT0045" ref-type="bibr">45</xref>, <xref rid="CIT0047" ref-type="bibr">47</xref>&#x02013;<xref rid="CIT0049" ref-type="bibr">49</xref>]. Reduction of CgA concentration was observed after successful treatment with radionuclide therapy [<xref rid="CIT0050" ref-type="bibr">50</xref>] and after liver transplantation due to massive organ metastases [<xref rid="CIT0051" ref-type="bibr">51</xref>]. Generally CgA determination may be a useful tool in monitoring the treatment of GEP-NETs, with the stipulation that an elevated CgA level before therapy was observed [<xref rid="CIT0023" ref-type="bibr">23</xref>].</p></sec><sec id="S20020"><title>Chromogranin A in the case of somatostatin analog therapy</title><p>In patients treated with somatostatin analogs (SSA), the relationship between circulating CgA and tumor mass is not obvious. This is due to the ability of SSA to block the production and secretion of chromogranin A [<xref rid="CIT0052" ref-type="bibr">52</xref>]. Chromogranin A concentration may correlate with tumor size, but care must be taken during interpretation of the results. Serial CgA measurements during follow-up should be performed at approximately the same intervals after the administration of a long-acting SSA.</p></sec><sec id="S20021"><title>Chromogranin A and other NET biomarkers</title><p>Chromogranin A can be regarded as an early model of neuroendocrine tumors originating from the foregut and midgut and seems to be a better marker of the disease than the assessment of urinal 5-HIAA and/or circulating serotonin concentrations. There is a stronger correlation between the concentration of CgA compared to 5HIAA with regard to the general condition and well-being of the patient, similar to the correlation between survival and the level of CgA, which makes CgA a recommended first-line marker for GEP-NETs [<xref rid="CIT0043" ref-type="bibr">43</xref>]. Another advantage in favor of CgA is definitely an easier way to collect samples for tests, compared to 24-hour 5HIAA urine collection. It should be remembered that in order to avoid false positive results of 5HIAA urine concentration, a special diet excluding numerous sources of tryptophan, such as bananas, cheese, chocolate, tomato, etc., should be introduced. In a study in which 127 patients with neuroendocrine tumors were enrolled, CgA demonstrated superiority over 5HIAA urine concentration, circulating neuron-specific enolase (NSE) and carcinoembryonal antigen (CEA) as a tumor marker [<xref rid="CIT0045" ref-type="bibr">45</xref>]. Although the specificity of both 5-HIAA and NSE was high (up to 100%), low sensitivity (35% and 33%, respectively) was observed. Comparing the data for CgA in this case, the specificity was 86% and sensitivity 68%. It is worth noting that CgA may be a marker for high sensitivity in the case of metastatic NET, but the concentration of 5-HIAA has the highest sensitivity in patients with the symptomatic hormonally active form of GEP-NET [<xref rid="CIT0037" ref-type="bibr">37</xref>].</p></sec></sec><sec id="S0022"><title>Chromogranin A potentially false-negative results</title><p>Chromogranin A concentration may be normal in the case of neuroendocrine tumors with a mild proliferative potential. These include the majority of neuroendocrine tumors of the appendix, which apart from a few cases are mostly benign tumors, which when totally excised do not require a follow-up after treatment. About 75% of insulinoma tumors are usually mild and CgA is usually not increased, but in this case the measurement of CgA may be a helpful indicator of tumor malignancy. Besides several typical lung carcinoids, duodenum and rectum low proliferative index tumors may not show elevation of circulating CgA [<xref rid="CIT0011" ref-type="bibr">11</xref>]. Rapidly proliferating, poorly differentiated neuroendocrine tumors, which in many cases lose their characteristic structure and show a much smaller number of secretory vesicles, may also not release the marker, giving false negative results.</p><p>Although CgA is not a specific marker for particular neuroendocrine tumors, one of its derivatives, neuroendocrine secretory protein 55 (NESP 55), seems to be a specific marker of pheochromocytoma and pancreatic neuroendocrine tumors, neuroendocrine tumors which are not present in the gut [<xref rid="CIT0053" ref-type="bibr">53</xref>]. However, so far this marker can be used only with immunohistochemical techniques, and it is impossible to use it as a circulating marker.</p></sec><sec id="S0023"><title>Other applications of chromogranin A</title><p>Chromogranin A assessment may be helpful for differentiating sources of high cortisol levels in the case of Cushing's disease between pituitary, adrenal and ectopic ACTH secretion by a neuroendocrine tumor. In the latter case, significantly higher levels of CgA compared to other cases are observed [<xref rid="CIT0054" ref-type="bibr">54</xref>].</p><p>There is a statistically significant difference in the concentration of CgA comparing benign and malignant pheochromocytomas [<xref rid="CIT0055" ref-type="bibr">55</xref>, <xref rid="CIT0056" ref-type="bibr">56</xref>]. The CgA concentrations in the case of malignant lesions were approximately 15 times higher compared to benign lesions. Also there was a positive correlation between CgA and tumor size in the adrenal gland [<xref rid="CIT0057" ref-type="bibr">57</xref>, <xref rid="CIT0058" ref-type="bibr">58</xref>]. Patients with adrenal tumors derived from the adrenal cortex usually do not have elevated circulating chromogranin A levels (especially in the case of incidentalomas) [<xref rid="CIT0059" ref-type="bibr">59</xref>]. Chromogranin A concentration correlates well with the production of catecholamines; therefore the determination of CgA is a complementary method to other laboratory tests in the diagnosis of pheochromocytoma such as 24-hour urine catecholamine collection. Determination of CgA concentration is an important tool in the differential diagnosis of pheochromocytoma as a cause of secondary hypertension [<xref rid="CIT0058" ref-type="bibr">58</xref>].</p></sec><sec sec-type="conclusions" id="S0024"><title>Conclusions</title><p>Sensitivity of CgA as a marker of neuroendocrine gastro-entero-pancreatic tumors depends on the location of the original tumor [<xref rid="CIT0060" ref-type="bibr">60</xref>, <xref rid="CIT0061" ref-type="bibr">61</xref>], metastatic cancer, especially liver metastases [<xref rid="CIT0023" ref-type="bibr">23</xref>, <xref rid="CIT0030" ref-type="bibr">30</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>, <xref rid="CIT0063" ref-type="bibr">63</xref>], and laboratory methodology: determining cutoff CgA [<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0034" ref-type="bibr">34</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>] and the use of a particular method for detection of CgA [<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>]. The greatest value of CgA as a marker of the disease is achieved in the case of metastatic disease to the liver. It is believed that improvement of the diagnostic sensitivity of CgA can be achieved by combining the measurement of its concentration with another diagnostic technique, especially scintigraphy or PET/CT based on somatostatin and its receptors. It is estimated that determination of CgA concentration and performing receptor scintigraphy with somatostatin analogs increases the sensitivity to 93%, whereas sensitivity of each of these techniques performed separately is estimated at 60&#x02013;80% [<xref rid="CIT0064" ref-type="bibr">64</xref>]. During the attempt to interpret the result of chromogranin A, caution is recommended, bearing in mind the multitude of factors that may lead to both false positive and negative results.</p></sec></body><back><sec id="S0025"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>P</given-names></name><name><surname>Helle</surname><given-names>K</given-names></name></person-group><article-title>The release of protein from the stimulated adrenal medulla</article-title><source>Biochem J</source><year>1965</year><volume>97</volume><fpage>40C</fpage><lpage>1C</lpage></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaschko</surname><given-names>H</given-names></name><name><surname>Comline</surname><given-names>RS</given-names></name><name><surname>Schneider</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchic stimulation</article-title><source>Nature</source><year>1967</year><volume>215</volume><fpage>58</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6053402</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>MP</given-names></name><name><surname>Levi</surname><given-names>R</given-names></name><name><surname>Ramella</surname><given-names>R</given-names></name><etal/></person-group><article-title>Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in the rat ventricular myocardium</article-title><source>Am J Physiol</source><year>2007</year><volume>292</volume><fpage>H2906</fpage><lpage>12</lpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasciotto</surname><given-names>BH</given-names></name><name><surname>Trauss</surname><given-names>CA</given-names></name><name><surname>Greeley</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Parastatin (porcine chromogranin A347-419), a novel chromogranin-derived peptide, inhibits paratharoid cell secretion</article-title><source>Endocrinology</source><year>1993</year><volume>133</volume><fpage>461</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8344192</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helman</surname><given-names>LJ</given-names></name><name><surname>Ahn</surname><given-names>TG</given-names></name><name><surname>Levine</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA</article-title><source>J Biol Chem</source><year>1988</year><volume>263</volume><fpage>11559</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">3403545</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>CV</given-names></name><name><surname>Taupenot</surname><given-names>L</given-names></name><name><surname>Mahata</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>22905</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10781584</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilek</surname><given-names>R</given-names></name><name><surname>Safarik</surname><given-names>L</given-names></name><name><surname>Ciprova</surname><given-names>P</given-names></name></person-group><article-title>Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma</article-title><source>Physiol Res</source><year>2008</year><volume>57</volume><issue>Suppl. 1</issue><fpage>S171</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18271679</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>Y</given-names></name><name><surname>Aunis</surname><given-names>D</given-names></name><name><surname>Bader</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Chromostatin, a chromogranin A-derived bioactive peptide, is present in human pancreatic insulin (beta) cells</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>2360</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8096340</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glinicki</surname><given-names>P</given-names></name><name><surname>Kapu&#x0015b;ci&#x00144;ska</surname><given-names>R</given-names></name><name><surname>Jeske</surname><given-names>W</given-names></name></person-group><article-title>The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods</article-title><source>Endokrynol Pol</source><year>2010</year><volume>61</volume><fpage>346</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20806177</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stridsberg</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>B</given-names></name><name><surname>Oberg</surname><given-names>K</given-names></name><etal/></person-group><article-title>A comparison between three commercial kits for chromogranin a measurements</article-title><source>J Endocrinol</source><year>2003</year><volume>177</volume><fpage>337</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12740022</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardill</surname><given-names>JE</given-names></name><name><surname>O'Dorosio</surname><given-names>TM</given-names></name></person-group><article-title>Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease an as prognostic indicators</article-title><source>Endocrinol Metab Clin N Am</source><year>2010</year><volume>39</volume><fpage>777</fpage><lpage>90</lpage></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pregun</surname><given-names>I</given-names></name><name><surname>Herszenyi</surname><given-names>L</given-names></name><name><surname>Juhasz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of proton-pump inhibitor therapy on serum chromogranin A level</article-title><source>Digestion</source><year>2011</year><volume>84</volume><fpage>22</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21304238</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>RJ</given-names></name><name><surname>Mezger</surname><given-names>MS</given-names></name><name><surname>O'Connor</surname><given-names>DT</given-names></name></person-group><article-title>Chromogranin A in uremia: progressive retention of immunoreactive fragments</article-title><source>Kidney Int</source><year>1990</year><volume>37</volume><fpage>955</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">2313983</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceconi</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Bachetti</surname><given-names>T</given-names></name><etal/></person-group><article-title>Chromogranin in heart failure: a novel neurohumoral factor and a predictor for mortality</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>967</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12069452</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>DP</given-names></name><name><surname>Onuoha</surname><given-names>GN</given-names></name><name><surname>McDowell</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neuroendocrine changes in chronic cardiac failure</article-title><source>Basic Res Cardiol</source><year>1996</year><volume>91</volume><issue>Suppl. 1</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8896739</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>Corti</surname><given-names>A</given-names></name><name><surname>Tota</surname><given-names>B</given-names></name><etal/></person-group><article-title>Myocardial production of chromogranin a in human heart: a new regulatory peptide of cardiac function</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>1117</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">17389654</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korse</surname><given-names>CM</given-names></name><name><surname>Taal</surname><given-names>BG</given-names></name><name><surname>de Groot</surname><given-names>CA</given-names></name><name><surname>Bakker</surname><given-names>RH</given-names></name><name><surname>Bonfrer</surname><given-names>JM</given-names></name></person-group><article-title>Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4293</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19667278</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>AM</given-names></name><name><surname>Rosjo</surname><given-names>H</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognostic value of circulating chromogranin A levels in acute coronary syndrome</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19028779</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiComte</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>CM</given-names></name><name><surname>Marinosci</surname><given-names>A</given-names></name><etal/></person-group><article-title>Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthitis and curbs TNF-alpha-elicited endothelial activation</article-title><source>J Leukoc Biol</source><year>2009</year><volume>85</volume><fpage>81</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18832606</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciola</surname><given-names>V</given-names></name><name><surname>Massironi</surname><given-names>S</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plasma chromogranin a in patients with inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2009</year><volume>15</volume><fpage>867</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">19090560</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeur</surname><given-names>J</given-names></name><name><surname>Milde</surname><given-names>AM</given-names></name><name><surname>Helle</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Low serum chromogranin A in patients with self-reported food hypersensitivity</article-title><source>Scand J Gastroenterol</source><year>2008</year><volume>43</volume><fpage>1403</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18654936</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fossmark</surname><given-names>R</given-names></name><name><surname>Jianu</surname><given-names>CS</given-names></name><name><surname>Martinsen</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition</article-title><source>Scand J Gastroenterol</source><year>2008</year><volume>43</volume><fpage>20</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18938772</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>B</given-names></name><name><surname>Gustafsson</surname><given-names>BI</given-names></name><name><surname>Kidd</surname><given-names>M</given-names></name><etal/></person-group><article-title>The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors</article-title><source>Endocrinol Metab Clin N Am</source><year>2011</year><volume>40</volume><fpage>111</fpage><lpage>34</lpage></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobels</surname><given-names>FR</given-names></name><name><surname>Kwekkeboom</surname><given-names>BJ</given-names></name><name><surname>Coopmans</surname><given-names>W</given-names></name><etal/></person-group><article-title>Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alfa-subunit of glycoprotein hormones</article-title><source>J Clin Endocr Metab</source><year>1997</year><volume>82</volume><fpage>2622</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9253344</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolf</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Bergh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Secretagogin is a new neuroendocrine marker in the human prostate</article-title><source>Prostate</source><year>2007</year><volume>67</volume><fpage>472</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">17285592</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tropea</surname><given-names>F</given-names></name><name><surname>Baldari</surname><given-names>S</given-names></name><name><surname>Restifo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours</article-title><source>Clin Drug Investig</source><year>2006</year><volume>26</volume><fpage>715</fpage><lpage>22</lpage></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names></name><name><surname>Aniel-Quiroga</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies</article-title><source>Tumor Biol</source><year>2011</year><volume>32</volume><fpage>13</fpage><lpage>22</lpage></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louthan</surname><given-names>O</given-names></name></person-group><article-title>Chromogranin A in physiology and oncology</article-title><source>Folia Biologica (Praha)</source><year>2011</year><volume>57</volume><fpage>173</fpage><lpage>81</lpage></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos-Kud&#x00142;a</surname><given-names>B</given-names></name><name><surname>Bolanowski</surname><given-names>M</given-names></name><name><surname>Handkiewicz-Junak</surname><given-names>D</given-names></name><etal/></person-group><article-title>Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by Polish Network of Neuroendocrine Tumors)</article-title><source>Endokrynol Pol</source><year>2008</year><volume>59</volume><fpage>41</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18335400</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasetti</surname><given-names>P</given-names></name><name><surname>Migliori</surname><given-names>M</given-names></name><name><surname>Simoni</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diagnostic value of plasma chromogranin A in neuroendocrine tumours</article-title><source>Eur J Gastroenterol Hepatol</source><year>2001</year><volume>13</volume><fpage>55</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11204811</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janson</surname><given-names>ET</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Strisberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a refferal center</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>685</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9296223</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobol</surname><given-names>RE</given-names></name><name><surname>Memoli</surname><given-names>V</given-names></name><name><surname>Deftos</surname><given-names>LJ</given-names></name></person-group><article-title>Hormone-negative, chromogranin A-positive endocrine tumors</article-title><source>N Engl J Med</source><year>1989</year><volume>320</volume><fpage>444</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2536475</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>R</given-names></name><name><surname>Wilke</surname><given-names>A</given-names></name><name><surname>Rinke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma chromogranin A as a marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors</article-title><source>Clin Gastroenterol Hepatol</source><year>2008</year><volume>6</volume><fpage>820</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18547872</pub-id></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Chardon</surname><given-names>L</given-names></name><name><surname>Chopin-Laly</surname><given-names>X</given-names></name><etal/></person-group><article-title>Is the combinantion of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>1766</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">22133573</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobels</surname><given-names>FR</given-names></name><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Chromogranin A: its clinical value as a marker of neuroendocrine tumours</article-title><source>Eur J Clin Invest</source><year>1998</year><volume>28</volume><fpage>431</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9693933</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>L</given-names></name><name><surname>Seregni</surname><given-names>E</given-names></name><name><surname>Lucignani</surname><given-names>G</given-names></name><etal/></person-group><article-title>Accuracy and clinical correlates of two different methods for chromogranin assay in neuroendocrine tumours</article-title><source>Int J Biol Markers</source><year>2004</year><volume>19</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">15646836</pub-id></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modlin</surname><given-names>IM</given-names></name><name><surname>Gustafsson</surname><given-names>BI</given-names></name><name><surname>Moss</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Chromogranin A- biological function and clinical utility in neuro endocrine tumor disease</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>2427</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">20217257</pub-id></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinik</surname><given-names>AI</given-names></name><name><surname>Silva</surname><given-names>MP</given-names></name><name><surname>Woltering</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biochemical testing for neuroendocrine tumors</article-title><source>Pancreas</source><year>2009</year><volume>38</volume><fpage>876</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">19855234</pub-id></element-citation></ref><ref id="CIT0039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Toole</surname><given-names>D</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>D</given-names></name><etal/></person-group><article-title>ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers</article-title><source>Neuroendocrinology</source><year>2009</year><volume>90</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">19713711</pub-id></element-citation></ref><ref id="CIT0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>BI</given-names></name><name><surname>Kidd</surname><given-names>M</given-names></name><name><surname>Modlin</surname><given-names>IM</given-names></name></person-group><article-title>Neuroendocrine tumors of the diffuse neuroendocrine system</article-title><source>Curr Opin Oncol</source><year>2008</year><volume>20</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18043250</pub-id></element-citation></ref><ref id="CIT0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehar</surname><given-names>D</given-names></name><name><surname>Lombard-Bohas</surname><given-names>C</given-names></name><name><surname>Olivieri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serum chromogranin A for diagnosis and follow-up of endocrine tumors</article-title><source>Clin Endocrinol (Oxf)</source><year>2004</year><volume>60</volume><fpage>644</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15104570</pub-id></element-citation></ref><ref id="CIT0042"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekeblad</surname><given-names>S</given-names></name><name><surname>Skogseid</surname><given-names>B</given-names></name><name><surname>Dunder</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prognostic factors and survival in 324 patients with pancreatic endocrine tumours treated at a single institution</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>7789</fpage><lpage>803</lpage></element-citation></ref><ref id="CIT0043"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korse</surname><given-names>CM</given-names></name><name><surname>Bonfrer</surname><given-names>JM</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Chromogranin A as an alternative to 5-hydroxyindolaecetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors</article-title><source>Neuroendocrinology</source><year>2009</year><volume>89</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">18840995</pub-id></element-citation></ref><ref id="CIT0044"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welin</surname><given-names>S</given-names></name><name><surname>Strisberg</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>J</given-names></name><etal/></person-group><article-title>Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors</article-title><source>Neuroendocrinology</source><year>2009</year><volume>89</volume><fpage>302</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19176944</pub-id></element-citation></ref><ref id="CIT0045"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Ferrari</surname><given-names>L</given-names></name><name><surname>Martinetti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chromogranin, neuron specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors</article-title><source>Cancer</source><year>1999</year><volume>86</volume><fpage>858</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10463986</pub-id></element-citation></ref><ref id="CIT0046"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>B</given-names></name><name><surname>Arnberg</surname><given-names>H</given-names></name><name><surname>Oberg</surname><given-names>K</given-names></name><etal/></person-group><article-title>Chromogranins &#x02013; new sensitive markers for neuroendocrine tumors</article-title><source>Acta Oncol</source><year>1989</year><volume>28</volume><fpage>325</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2545231</pub-id></element-citation></ref><ref id="CIT0047"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granberg</surname><given-names>D</given-names></name><name><surname>Wilander</surname><given-names>E</given-names></name><name><surname>Stridsberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical symptoms, hormone profiles, treatment and prognosis with gastric carcinoids</article-title><source>Gut</source><year>1998</year><volume>43</volume><fpage>223</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10189848</pub-id></element-citation></ref><ref id="CIT0048"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stivanello</surname><given-names>M</given-names></name><name><surname>Berutti</surname><given-names>A</given-names></name><name><surname>Torta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><issue>Suppl. 2</issue><fpage>S73</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11762356</pub-id></element-citation></ref><ref id="CIT0049"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shojamanesh</surname><given-names>H</given-names></name><name><surname>Gibril</surname><given-names>F</given-names></name><name><surname>Louie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>331</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11900219</pub-id></element-citation></ref><ref id="CIT0050"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><name><surname>Teunissen</surname><given-names>JJ</given-names></name><name><surname>Bakker</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Radiolabeled somatostatin analog [177-Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2754</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15837990</pub-id></element-citation></ref><ref id="CIT0051"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olausson</surname><given-names>M</given-names></name><name><surname>Friman</surname><given-names>S</given-names></name><name><surname>Herlenius</surname><given-names>G</given-names></name><etal/></person-group><article-title>Orthotropic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors</article-title><source>Liver Transpl</source><year>2007</year><volume>13</volume><fpage>327</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">17318853</pub-id></element-citation></ref><ref id="CIT0052"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinke</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>HH</given-names></name><name><surname>Schade-Brittinger</surname><given-names>C</given-names></name><etal/></person-group><article-title>Placebo-controlled, double-blind, prospective, randomized study on effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4656</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19704057</pub-id></element-citation></ref><ref id="CIT0053"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Padilla</surname><given-names>O</given-names></name><name><surname>Fischer-Colbrie</surname><given-names>R</given-names></name><etal/></person-group><article-title>Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids</article-title><source>Am J Surg Pathol</source><year>2004</year><volume>28</volume><fpage>1371</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15371954</pub-id></element-citation></ref><ref id="CIT0054"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobels</surname><given-names>FR</given-names></name><name><surname>de Herder</surname><given-names>WW</given-names></name><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Serum chromogranin A in the differential diagnosis of Cushing's syndrome</article-title><source>Eur J Endocrinol</source><year>1994</year><volume>131</volume><fpage>589</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">7528607</pub-id></element-citation></ref><ref id="CIT0055"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>HZ</given-names></name><name><surname>Yan</surname><given-names>WG</given-names></name><etal/></person-group><article-title>The expression and significance of chromogranin A and synaptophysin in adrenal gland tumors</article-title><source>Zhonghua Zhong Liu Za Zhi</source><year>2005</year><volume>27</volume><fpage>486</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16188147</pub-id></element-citation></ref><ref id="CIT0056"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portela-Gomes</surname><given-names>GM</given-names></name><name><surname>Stridsberg</surname><given-names>M</given-names></name><name><surname>Grimelius</surname><given-names>L</given-names></name><etal/></person-group><article-title>Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immunohistochemical study with region-specific antibodies</article-title><source>APMIS</source><year>2004</year><volume>112</volume><fpage>663</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15601318</pub-id></element-citation></ref><ref id="CIT0057"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovanella</surname><given-names>L</given-names></name><name><surname>Squin</surname><given-names>N</given-names></name><name><surname>Ghelfo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan</article-title><source>Q J Nucl Med Mol Imaging</source><year>2006</year><volume>50</volume><fpage>344</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17043632</pub-id></element-citation></ref><ref id="CIT0058"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Herbomez</surname><given-names>M</given-names></name><name><surname>Gouze</surname><given-names>V</given-names></name><name><surname>Huglo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma</article-title><source>J Nucl Med</source><year>2001</year><volume>42</volume><fpage>993</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11438617</pub-id></element-citation></ref><ref id="CIT0059"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernini</surname><given-names>GP</given-names></name><name><surname>Moretti</surname><given-names>A</given-names></name><name><surname>Borgioli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma and tissue chromogranin in patients with adrenocortical adenomas</article-title><source>J Endocrinol Invest</source><year>2004</year><volume>27</volume><fpage>821</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15648545</pub-id></element-citation></ref><ref id="CIT0060"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurman</surname><given-names>G</given-names></name><name><surname>Raeth</surname><given-names>U</given-names></name><name><surname>Wiedenmann</surname><given-names>B</given-names></name><etal/></person-group><article-title>Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract</article-title><source>World J Surg</source><year>1992</year><volume>16</volume><fpage>697</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">1413839</pub-id></element-citation></ref><ref id="CIT0061"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudin</surname><given-names>E</given-names></name><name><surname>Bihart</surname><given-names>JM</given-names></name><name><surname>Bachelot</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of chromogranin A measurement in the work-up of neuroendocrine tumors</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>S79</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11762357</pub-id></element-citation></ref><ref id="CIT0062"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zatelli</surname><given-names>MC</given-names></name><name><surname>Torta</surname><given-names>M</given-names></name><name><surname>Leon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chromogranin A as a marker of neuroendocrine neoplasia. An Italian Multicenter Study</article-title><source>Endocr Relat Cancer</source><year>2007</year><volume>14</volume><fpage>473</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">17639060</pub-id></element-citation></ref><ref id="CIT0063"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikou</surname><given-names>GC</given-names></name><name><surname>Marinou</surname><given-names>K</given-names></name><name><surname>Thomakos</surname><given-names>P</given-names></name><etal/></person-group><article-title>Chromogranin A levels in diagnosis treatment and follow up of 42 patients with non functioning pancreatic endocrine tumors</article-title><source>Pancreatology</source><year>2008</year><volume>8</volume><fpage>510</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18765956</pub-id></element-citation></ref><ref id="CIT0064"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namwongprom</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>FC</given-names></name><name><surname>Tateishi</surname><given-names>U</given-names></name><etal/></person-group><article-title>Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tomours</article-title><source>Ann Nucl Med</source><year>2008</year><volume>22</volume><fpage>237</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">18535873</pub-id></element-citation></ref></ref-list></back></article>